In recenti colloquium, Dr. Afsaneh Barzi, adiutorem professor a Universitatis Australium California orci medicina cum Norisio Comprehensive Cancer Center, indicavit tibi quod existentium novo emergentes adjuvant therapies pro aegris cum non-metastatic pancreaticum cancer.
Pancreaticum cancer cum aegris Gemcitabine datum est in usu vexillum responsum est aestimare. Autem, dicitur quod Barzi patientes estote ad responsionem esset gemcitabine pauperrimus et multis aegris quæ'sumus ut esset non poterat. Et inquisiverunt LAPACT iudicium ex aggregatione illic et gemcitabine-nab paclitaxel (Abraxane). XXXVI% probat ostendit quod cancer aegris Respondeo dicendum est curatio pancreaticum, ductum pancreaticum cancer et de XV% de aegris potest accipere chirurgicam doctoris elit.
In addition, a meta-analysis of the FOLFIRINOX study of patients with locally advanced pancreatic cancer showed that approximately 28% of pancreatic cancer patients were able to undergo surgery. Barzi explained that as chemotherapy becomes more effective, the likelihood of resection increases. Therefore, the patient’s resection should be evaluated accordingly. Barzi concluded that although most patients may still not be eligible for surgery, it is still worth evaluating patients to find patients who can undergo surgery after neoadjuvant therapy.
